Background A recent trial of 5920 children in Burkina Faso and Mali showed that the
combination of seasonal vaccination with the RTS, S/AS01E malaria vaccine (primary series …

Progress toward developing a vaccine against malaria has been slow, but in October of this
year, the World Health Organization recommended widespread use of the RTS, S/AS01 …

In 2013, 200 million people were infected with malaria, resulting in over 584,000 deaths,
with the potential to affect over half the world's population. Such is the widespread nature of …

The first clinical Phase III trial evaluating a malaria vaccine was completed in December
2013 at 11 sites from seven sub-Saharan African countries. This systematic review assesses …

Abstract The Malaria Vaccine Technology Roadmap calls for a 2015 landmark goal of a first-
generation malaria vaccine that has protective efficacy against severe disease and death …

Background The Malaria Vaccine Implementation Program, coordinated by the World Health
Organization, intended to initiate the roll-out of the RTS, S/AS01 malaria vaccine in 3 sub …

Prior to progression to Clinical Development Phase III, GlaxoSmithKline Biologicals
performed a pooled analysis of phase two safety data following administration of 8860 …

Abstract RTS, S/AS01 (Mosquirix®) is a vaccine against malaria caused by Plasmodium
falciparum. In a phase 3 trial, RTS, S/AS01 showed vaccine efficacy against clinical malaria …

Background Adding malaria vaccination to existing interventions could help to reduce the
health burden due to malaria. This study modelled the potential public health impact of the …

The RTS, S vaccine has recently been recommended for implementation as a childhood
vaccine in regions with moderate-to-high malaria transmission. We discuss mechanisms of …